Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Cervical cancer
Stage/Subtype:  stage III cervical cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 27 for your search:
Start Over
Intensity Modulated Radiation Therapy in Treating Patients with Cervical Cancers
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 110808, NCI-2012-02858, NCT01554397
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: ANZGOG-0902/GOG-0274/RTOG-1174, NCI-2011-02978, ANZGOG-0902, CDR0000706698, GOG-0274, RTOG-1174, ANZGOG-0902-GOG-0274, NCT01414608
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: HPV-004, NCI-2015-00497, NCT02172911
A Study to Investigate the Safety and Efficacy of Nivolumab and Nivolumab Plus Ipilimumab in Virus-associated Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5C-11-2, NCI-2012-01378, HS-11-00547, NCT01676818
Image Guided Hypofractionated Radiation Therapy in Treating Patients with Stage IB-IVB Cervical Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 082013-064, NCI-2015-01672, NCT02045433
Nivolumab and Synthetic Long E6/E7 Peptides Vaccine HPV-01 in Treating Patients with Recurrent or Metastatic Incurable HPV-16-Positive Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-1047, NCI-2015-01004, NCT02426892
Radiation Therapy and Cisplatin with or without Triapine in Treating Patients with Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY006, NCI-2015-00835, NCT02466971
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Nanoparticle Albumin-Bound Rapamycin in Treating Patients with Advanced Cancer with mTOR Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1313, NCI-2015-02151, NCT02646319
Z-endoxifen Hydrochloride in Treating Patients with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0061, NCI-2013-01475, 110061, P10725, 8826, NCT01273168
Intensity-Modulated Radiation Therapy, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Stage IB-IVA Cervical Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 100597, NCI-2012-02860, NCT01554410
Chemoradiation Therapy and Ipilimumab in Treating Patients with Locally Advanced Cervical Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-9929, NCI-2012-01733, GOG-PIS1102, NCT01711515
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA224-020, NCI-2014-00315, 2014-002605-38, NCT01968109
A Study of Coti-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: COTI2-101, NCI-2015-01738, NCT02433626
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PM60184-A-003-14, NCI-2015-01510, 2014-002943-16, NCT02533674
Study of E7046 in Subjects With Selected Advanced Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E7046-G000-101, NCI-2015-01544, NCT02540291
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: GEN702, NCI-2015-01770, NCT02552121
Triapine with Chemotherapy and Radiation Therapy in Treating Patients with IB2-IVA Cervical or Vulvar Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 15-157, NCI-2015-01907, 15-157, 9892, NCT02595879
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, NCT02631733
A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR108083, NCI-2016-00673, 61610588LUC1001, NCT02671955
Start Over